MIAMI, Florida — Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation oral macrocyclic MEK inhibitor for the treatment of chronic diseases, including neurofibromatosis type 1 (NF1)-associated neurofibromas, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational...

CAMBRIDGE, Mass. –Progentos Therapeutics, a biotechnology company developing regenerative medicines for multiple sclerosis (MS) and other demyelinating diseases, today announced that the first participant has been dosed in its Phase 1/2a clinical trial of PRO-1562 (NCT07826689). PRO-1562 is a novel oral small molecule designed to regenerate myelin in patients with...

MADRID, Spain and CAMBRIDGE, Mass. – Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced that VIVALDI, a Phase Ib pilot study sponsored by CETLAM — Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplásicas, has been authorized in...